Merit Medical Systems, Inc. announced on October 15, 2025 that it had entered into an asset purchase agreement with PENTAX Medical, a division of HOYA Group, to acquire the C2 CryoBalloon™ technology. The deal adds a minimally invasive cryotherapy device used to treat Barrett’s esophagus and other gastrointestinal disorders to Merit’s Endoscopy portfolio.
The acquisition is projected to generate roughly $6 million to $8 million in revenue in 2026, providing a new revenue stream that complements Merit’s existing upper‑GI products. The transaction also expands Merit’s market reach in the gastroenterology segment, where the company already has a strong commercial footprint.
Manufacturing of the C2 CryoBalloon will be transferred to Merit’s South Jordan, Utah facility, and several PENTAX employees will join Merit to support the integration. The move is expected to accelerate product commercialization and leverage Merit’s established distribution network in the United States and internationally.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.